A planned preclinical study will compare MicronJet’s suprachoroidal administration with existing methods, testing whether it can place exosome formulations consistently near the retina and optic nerve.
The initial program will use qualified perinatal starting materials and the licensed Dezawa Method, with product-specific testing and release criteria.
The analyses track skeletal muscle and heart outcomes through 24 months in 82 of 106 randomized participants, including delayed-start and natural-history comparisons submitted with a regulatory amendment.
The combined company operates 16 qualified manufacturing suites across three U.S. sites, supporting cell therapy programs from early development through commercial supply.
Researchers administered the vesicles intranasally over time to female mice genetically engineered to model Alzheimer’s and separately tested them in neurons grown from patients’ induced pluripotent stem cells.
NurExone's SCI candidate showed 100% gait recovery in rat models, and they're gearing up for human trials hopefully in 2026. Enjoy the interview!
Researchers are testing whether exosomes from umbilical cord stem cells can safely reduce inflammation and support cartilage repair in osteoarthritis.
NurExone secures U.S. patent protection for its exosome production method, supporting scale-up and clinical supply chain readiness.
Nurexone Biologic has developed an exosome therapy for nerve repair, we interviewed the CEO, Dr. Lior Shaltiel here. Enjoy!
Independent analysis finds NurExone’s exosomes deliver enhanced regenerative signals, showing promise for nerve repair and tissue healing applications.
